The FDA has approved suzetrigine, a medication designed to treat post-injury or surgery pain without the risk of addiction found in opioids. Manufactured by Vertex Pharmaceuticals and marketed under the name Journavx, it functions by blocking pain signals outside the brain. Clinical trials involving around 2,000 participants demonstrated similar side effects to placebos, confirming its safety. Priced at $15.50 per pill, suzetrigine is seen as a breakthrough in creating more powerful, non-addictive pain relief options while addressing the opioid crisis.
The FDA has approved suzetrigine, a non-addictive pain medication, which blocks pain signals without affecting the brain, offering a promising alternative to opioids.
Suzetrigine, developed by Vertex Pharmaceuticals, presents a new class of pain relief that is expected to mitigate the concerns of addiction associated with current opioids.
Collection
[
|
...
]